kaleo announced the upcoming launch of Auvi-Q (epinephrine injection) 0.1mg for the treatment of life-threatening allergic reactions, including anaphylaxis, in infants and toddlers weighing 16.5 to 33lbs.
The new 0.1mg strength auto-injector has a shorter needle length and is the first approved epinephrine auto-injector for this patient group. The low-dose auto-injector features a retractable needle and a voice guide system that instructs caregivers step-by-step through the injection process like the other Auvi-Q auto-injector strengths (0.15mg and 0.3mg).
The supplemental New Drug Application (sNDA) for the 0.1mg strength was granted Priority Review by the Food and Drug Administration (FDA).
Epinephrine is a non-selective alpha and beta-adrenergic receptor agonist that works by reducing the vasodilation and increased vascular permeability that occurs during anaphylaxis.
Auvi-Q 0.1mg will be available as a carton containing 2 auto-injectors and 1 Trainer injector. The product will be available on May 1, 2018.
For more information call (804) 545-6360 or visit Auvi-Q.com.
This article originally appeared on MPR